Comparison Between Transpapillary and Suprapapillary Metal Stent
1 other identifier
interventional
156
1 country
1
Brief Summary
If surgical treatment is not possible in patients with malignant obstruction in the common bile duct, placing metal stents using endoscopy is a standardized treatment to resolve biliary obstruction. The metal stent is located in the bile duct to cover the stenotic portion by malignant tumors. The lower end of the metal stent can be located inside the common bile duct above the major ampulla or in the duodenum through the major ampulla. These two procedures with supra- or trans-papillary stents are currently being performed in general clinical practices, depending on the preference of the endoscopists. Until now, the comparison of the clinical results of the two procedures has been scarcely studied, and there is no prospective study yet. Therefore, researchers aim to compare the clinical results of two stent procedures through prospective randomized controlled studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 30, 2020
CompletedFirst Posted
Study publicly available on registry
August 7, 2020
CompletedStudy Start
First participant enrolled
January 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 12, 2023
CompletedJuly 22, 2022
July 1, 2022
2.7 years
July 30, 2020
July 19, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Stent function maintenance duration
jaundice free survival
through study completion, an average of 1 year
Secondary Outcomes (5)
stone or sludge occurrence
through study completion, an average of 1 year
in-stent stenosis or tumor overgrowth
through study completion, an average of 1 year
acute cholangitis occurrence
through study completion, an average of 1 year
stent migration rate
through study completion, an average of 1 year
overall survival
From date of randomization until the date of date of death from any cause, assessed up to 36 months
Study Arms (2)
supra-papillary metal stent group
EXPERIMENTALThe distal ends of metal stents are located above the major papilla in the common bile duct.
trans-papillary metal stent group
ACTIVE COMPARATORThe distal ends of metal stents are located below the major papilla in the duodenum.
Interventions
Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Eligibility Criteria
You may qualify if:
- patients with common bile duct obstruction due to malignancy
You may not qualify if:
- intrahepatic or perihilar bile duct obstruction (except Klatskin type I)
- patients who have operability or want surgery
- strictures located within 2 cm from the end of distal common bile duct
- patients who are not able to undergo endoscopy due to cardiovascular or pulmonary diseases
- patients whose informed consents are not received
- patients in whom an endoscope can not access to the ampulla due to anatomical deformity by previous surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bucheon St. Mary's Hospitallead
- Seoul St. Mary's Hospitalcollaborator
- Incheon St.Mary's Hospitalcollaborator
- St Vincent's Hospitalcollaborator
Study Sites (1)
Jae Hyuck Chang
Bucheon-si, Kyunggi, 14647, South Korea
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- Assigned groups are secreted to the participant and outcome assessors
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 30, 2020
First Posted
August 7, 2020
Study Start
January 4, 2021
Primary Completion
October 1, 2023
Study Completion
December 12, 2023
Last Updated
July 22, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Immediately following publication. No end date
- Access Criteria
- * Investigators whose proposed use of the data has been approved by an independent review committee * To achieve aims in the approved proposal * Proposals may be submitted up to 36 months following article publication.
All of the individual participant data collected during the trial, after deidentification.